Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors
Harish Seethapathy(Harvard University), Meghan E. Sise(Harvard University), Marina D. Kaymakcalan(Dana-Farber Cancer Institute), David E. Leaf(Brigham and Women's Hospital), M. Dror Michaelson(Harvard University), Kerry L. Reynolds(Massachusetts General Hospital), Xiao X. Wei(Dana-Farber Cancer Institute), Shruti Gupta(Harvard University), Donald F. Chute(Massachusetts General Hospital), Guru Sonpavde(AdventHealth Orlando), Toni K. Choueiri(Harvard University), Cristina Salabao(Dana-Farber Cancer Institute), Meghan Lee(Massachusetts General Hospital), Shveta S. Motwani(Brigham and Women's Hospital), Ian A. Strohbehn(Massachusetts General Hospital), Osama E. Rahma(Dana-Farber/Harvard Cancer Center), Xīn Gào(Qingdao University), Sophia H. Zhao(Massachusetts General Hospital), Sarah E. Street(Massachusetts General Hospital), Brad McGregor(Dana-Farber Cancer Institute), Nifasha Rusibamayila(Massachusetts General Hospital)
Cited by 17
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
|Journal of the American College of Cardiology|2018|1.5k
Aberrant CpG-island methylation has non-random and tumour-type–specific patterns
|Nature Genetics|2000|1.4k